MNOV vs CBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

MNOV

50.8
AI Score
VS
MNOV Wins

CBIO

41.1
AI Score

Investment Advisor Scores

MNOV

51score
Recommendation
HOLD

CBIO

41score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MNOV CBIO Winner
Revenue 645,423 1.04M CBIO
Net Income -4.90M -48.12M MNOV
Net Margin -759.3% -4631.4% MNOV
Operating Income -5.38M -51.09M MNOV
ROE -13.1% -29.5% MNOV
ROA -12.1% -26.3% MNOV
Total Assets 40.43M 182.76M CBIO
Cash 25.42M 171.59M CBIO
Current Ratio 8.75 9.66 CBIO
Free Cash Flow -5.40M -28.56M MNOV

Relative Price Performance (Last 90 Days)

MNOV 1M: -4.1% · 3M: +7.6% CBIO 1M: +17.0% · 3M: -14.1%

Current Technical Phase

MNOV

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 41

RSI (14): 40.7 · Price: $1.41

CBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 57

RSI (14): 57.3 · Price: $14.72

Fundamentals Snapshot

Metric MNOV CBIO
Market Cap — —
Forward P/E -2.7 -5.6
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 2.4% 0.0%
Gross Margin 0.4% 1.0%
Operating Margin -5.5% -14.3%
EPS -0.21 -7.63
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, MNOV is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.